<DOC>
	<DOCNO>NCT00383149</DOCNO>
	<brief_summary>The purpose clinical research study learn ixabepilone plus cetuximab improves survival give 1st line chemotherapy subject metastatic pancreatic cancer compare historical data . The safety combination treatment also study .</brief_summary>
	<brief_title>A Phase II , Trial Ixabepilone Plus Cetuximab First Line Therapy Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologic cytologic diagnosis pancreatic adenocarcinoma ( locally advance disease surgically resectable , distant metastatic disease ) Participants must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) guideline Participants must receive prior chemotherapy , immunotherapy chemoradiotherapy advance pancreas cancer Karnofsky performance status ( KPS ) 70100 Adequate hematologic , hepatic renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>